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Abstract
The expression of estrogen receptor alpha (ERα, encoded by ESR1) has been shown to be associated with the
prognostic outcomes of patients in various cancers; however, its prognostic and mechanistic significance in
hepatocellular carcinoma (HCC) remain unclear. Here, we evaluated the expression of ERα and its association with
clinicopathological features in 339 HCC patients. ERα was expressed in 9.4% (32/339) of HCCs and was related to better
overall survival (OS; hazard ratio [HR]= 0.11, p= 0.009, 95% C.I.= 0.016–0.82) and disease-free survival (DFS, HR= 0.4,
p= 0.013, 95% C.I.= 0.18–0.85). ERα expression was also associated with features related to more favorable prognosis,
such as older age, lower serum alpha-fetoprotein level, and less microvascular invasion (p < 0.05). In addition, to obtain
mechanistic insights into the role of ERα in HCC progression, we performed integrative transcriptome data analyses,
which revealed that yes-associated protein (YAP) pathway was significantly suppressed in ESR1-expressing HCCs. By
performing cell culture experiments, we validated that ERα expression enhanced YAP phosphorylation, attenuating its
nuclear translocation, which in turn suppressed the downstream signaling pathways and cancer cell growth. In
conclusion, we suggest that ERα expression is an indicator of more favorable prognosis in HCC and that this effect is
mediated by inactivation of YAP signaling. Our results provide new clinical and pathobiological insights into ERα and
YAP signaling in HCC.
Introduction
Hepatocellular carcinoma (HCC) is a highly malignant
tumor with a dismal clinical prognosis. The incidence of
HCCs is three times higher in males than in females1.
Moreover, male patients showed worse overall survival
(OS) than female patients2, implying that sex differences
play an important role in HCC progression. Indeed, the
sex hormone estrogen and the estrogen receptor (ER)
have been found to be associated with the progression of
various cancers, including breast cancer, ovarian cancer,
and HCC3,4.
The two major isoforms of ER are ERα (encoded by
ESR1) and ERβ (encoded by ESR2), and ERα is the most
abundant isoform in HCC5. Experimental studies have
shown that ERα suppresses growth and inflammatory
processes in diverse cancer types, including HCC, color-
ectal cancer, and gastric cancer6–8. Consistent with this
observation, several studies have suggested that the
expression of ERα is associated with better prognosis of
HCC patients9,10. However, these studies were performed
with a limited sample size, requiring further extended
evaluation. Moreover, the precise mechanisms by which
ERα affects cancer progression are not yet clear.
In this study, to determine the prognostic significance of
ERα in HCC patients, we performed an extensive tissue
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microarray (TMA) analysis of 339 HCC samples, which
revealed that ERα expression is an independent indicator
of better prognostic outcomes in HCC patients. In addi-
tion, the results of our transcriptome data analyses sug-
gested that inactivation of YAP may mediate the tumor-
suppressive function of ERα in HCCs. YAP and tran-
scriptional coactivator with PDZ-binding motif (TAZ) are
the major downstream effectors of the Hippo pathway,
which regulates tissue homeostasis, regeneration, and
tumorigenesis11–13. Activation of YAP or inhibition of
upstream Hippo molecules such as the serine/threonine-
protein kinases MST1/2 and large tumor suppressor
kinase 1 (LATS1) can lead to nuclear translocation of
YAP, which in turn promotes the tumorigenesis and
progression of various cancers14,15. However, the effect of
ERα expression on Hippo/YAP signaling has not yet been
fully elucidated. In this study, we demonstrated that ERα
expression can attenuate YAP signaling, resulting in
suppression of HCC progression. Our results may provide
new insights into the clinical and pathobiological sig-
nificance of ERα and YAP signaling in HCC progression.
Materials and Methods
Patients and specimens
Patients who were diagnosed with HCC and underwent
curative hepatic resection between May 2000 and Feb-
ruary 2011 at Severance Hospital, Yonsei University
Medical Center, were enrolled. A total of 339 HCC
patients were included in the study, and patients with
combined hepatocellular cholangiocarcinoma were
excluded. None of the patients had received any pre-
operative treatment, such as transarterial chemoemboli-
zation, percutaneous ethanol injection, radiofrequency
ablation, radiation, or systemic chemotherapy. Electronic
medical records were reviewed to obtain clinical data,
including age, sex, etiology, blood count, and the serum
levels of aspartate transaminase, alanine transaminase,
albumin, and the tumor marker alpha-fetoprotein (AFP).
Histopathologic examination was performed on whole-
section hematoxylin-eosin-stained slides prepared from
representative formalin-fixed, paraffin-embedded tissue
blocks. The following variables were evaluated: tumor
size, Edmondson–Steiner grade, tumor multiplicity,
tumor capsule formation, presence of microvascular
invasion, and fatty change in the tumor.
Patients were routinely followed up by computed tomo-
graphy or magnetic resonance imaging at intervals of
3–6 months. OS was defined as the time from surgery to
death, and DFS was defined as the time from surgery to
initial diagnosis of recurrence regardless of location. The
mean follow-up time after surgery was 43.0 ± 20.72 months
(0–146). The study was approved by the Institutional Review
Board of Severance Hospital (IRB No. 4–2018–0748), and
the requirement for informed consent was waived.
Construction of tissue microarrays and
immunohistochemistry
TMAs of HCC specimens were constructed using two
core biopsies of 2 mm in diameter, which were obtained
from paraffin-embedded sections of tissue specimens and
arranged into recipient TMA blocks using a trephine
apparatus (Superbiochips Laboratories, Seoul, Korea).
Immunohistochemistry was performed using antibodies
against ERα, EpCAM, K19, CD133, CD24, S100P, and
YAP. Brown membranous and/or cytoplasmic staining
was considered positive for EpCAM, K19, and CD133;
cytoplasmic staining, for CD24; and nuclear staining, for
ERα and S100P. Positivity for nuclear and cytoplasmic
expression of YAP was concluded if more than 50% of the
tumor cells were stained with strong intensity. The details
on the antibodies and the experimental conditions are
summarized in Supplementary Table S1.
Transcriptome data analysis
Public data from The Cancer Genome Atlas-Liver
Hepatocellular Carcinoma (TCGA-LIHC) dataset were
obtained by using the TCGAbiolinks package in R soft-
ware16, and the GSE87630, GSE4024, and GSE14520
datasets were obtained from the NCBI GEO database
(https://www.ncbi.nlm.nih.gov/geo/). Integration of the
datasets was performed by correcting batch effects using
the “Combat” library in R software. Samples with normal
tissues were excluded from the datasets.
Gene set analyses were performed using the gProfileR
(0.7.0) package in R software and data from the KEGG
(http://www.genome.jp/kegg/) and REAC (http://www.
reactome.org/) databases. Coordinated gene regulation was
identified using GSEA (https://www.gsea-msigdb.org/gsea,
version 3.0). Gene sets from previous studies, including the
gene sets for stemness/stem cell genes17 and the prognostic
HCC classifiers of Hoshida’s classification18 and Boyault’s
classification19. Prediction of the HCC groups by the prog-
nostic classifiers was performed with the nearest template
prediction (NTP) algorithm with a false discovery rate (FDR)
<0.05 as the criterion for statistical significance as described
previously20. Detailed information on the datasets is pro-
vided in Supplementary Table S2.
The oncoactivity score was calculated based on the
differential enrichment of oncogene activation tumor
suppressor gene (TSG) repression as follows: Oncoactiv-
ity= ESoncogene− ESTSG, where ES was the calculated
enrichment score of the indicated genes. The lists of
oncogenes (n= 674)21 and TSGs (n= 1088)22 were
obtained from previous studies.
Cell culture
The human HCC cell lines HepG2 and Hep3B were
purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and grown in minimum
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essential medium (MEM, Gibco, Carlsbad, MD, USA),
Dulbecco’s modified Eagle’s medium (DMEM, Gibco), and
Roswell Park Memorial Institute 1640 medium (RPMI 1640,
Gibco) supplemented with 10% fetal bovine serum (Gibco),
100U/mL penicillin, and 100 μg/mL streptomycin at 37 °C
in a humidified atmosphere with 5% CO2.
Cloning and establishment of overexpression cell lines
For the cloning of tagged ESR1 coding gene sequences
into pCDH-CMV-EF1-puro, the ESR1 gene was amplified
using total RNA extracted from normal liver tissue. PCR
was performed using specific primers containing a 5′-
extension and NotI (NEB, Ipswich, MA, USA) and XbaI
(NEB) restriction sites with CloneAmp HiFi PCR Premix
(Thermo Fisher Scientific, San Jose, CA, USA). Subse-
quently, the amplicons were digested with NotI and XbaI
and cloned into the pCDH-CMV-EF1-puro vector using
an In-Fusion® cloning system according to the manu-
facturer’s recommendations. The details of the primer
sequences and thermal cycling conditions are summar-
ized in Supplementary Table S3.
HepG2 and Hep3B cells were transfected with pCDH-
CMV-EF1-puro containing the tagged ESR1 coding
sequence along with the gag-pol and VSV-G plasmids
(plasmids 14887 and 8454, respectively; Addgene, Cam-
bridge, MA, USA) using Lipofectamine® 3000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
recommendations. After transfection, stable ESR1-
expressing cells were selected with 0.5–1.0 µg/mL pur-
omycin (Sigma-Aldrich Co., St. Louis, MO, USA) for
4 weeks. To confirm the specificity and efficiency of ESR1
overexpression, we analyzed mRNA and protein expres-
sion using qRT-PCR and Western blotting.
Immunofluorescence analysis
Hep3B cells were seeded on microscope cover glasses in
12-well plates. After 24 h, the cells were fixed with 4%
paraformaldehyde for 30min. After permeabilization with
PBS containing 0.2% Tween 20 for 30min at 4 °C, the cells
were blocked with freshly prepared 2% bovine serum
albumin (BSA) for 1 h. The fixed cells were stained with
an anti-YAP (1:400, sc-271134, Santa Cruz) antibody in
2% BSA for an hour at room temperature and then with
Alexa Fluor® 488-conjugated goat anti-mouse IgG as the
secondary antibody for 1 h at room temperature. Finally,
the cells were washed with cold PBS, and the cover glasses
were mounted with DAKO® Fluorescent Mounting
Medium (DakoCytomation, Carpinteria, CA, USA). The
cells were examined under a TCS SP5 confocal micro-
scope system (Leica, Deerfield, IL, USA).
Dual-luciferase reporter assay
Cells were cotransfected with 100 ng of each reporter
construct and 0.25 ng of the pNL1.1.TK vector
(Promega, Madison, WI, USA) per well in white-bottom
96-well plates (SPL Life Science, Pocheon, Korea) using
0.5 µl of FuGENE® HD Transfection Reagent (Pro-
mega). To determine the effect of YAP/TEAD promoter
activity, cells in each well were cotransfected with
reporter constructs such as pGL3.0-basic (Promega)
and 8xGITTC-luciferase (Addgene, plasmid #34615,
Cambridge, MA, USA) and the pNL1.1.TK vector.
Forty-eight hours post transfection, luciferase activity
was measured with a Nano-Glo® Dual Luciferase®
Reporter Assay System (Promega) according to the
manufacturer’s recommendations. Relative firefly luci-
ferase activity was normalized to NanoLuc™ luciferase
activity to adjust for variations in the transfection
efficiency.
Western blotting and quantitative real-time PCR analysis
The primary antibodies used were rabbit anti-ERα
(8644, Cell Signaling Technology [CST], Danvers, MA,
USA), rabbit anti-phospho-YAP/S109 (13008, CST), rab-
bit anti-phospho-YAP/S127 (4911, CST), rabbit anti-YAP
(14074, CST), rabbit anti-phospho-LATS/S1079 (8654,
CST), rabbit anti-LATS1 (3477, CST), rabbit anti-phos-
pho-MST1/2/T183/180 (3681, CST), rabbit anti-MST1
(3681, CST), rabbit anti-GAPDH (2118, CST), and rabbit
anti-Histone H3 (cs-10809, Santa Cruz, California, CA,
USA). Horseradish peroxidase-conjugated anti-rabbit IgG
(7047, CST) and anti-mouse IgG (7076, CST) were used
as secondary antibodies (for details, see Supplementary
Table S1).
Quantitative real-time PCR was performed using iQTM
SYBR Supermix (Bio-Rad, Hercules, CA, USA). The
details of the primer sequences and thermal cycling
conditions are summarized in Supplementary Table S3.
siRNA-mediated knockdown experiments
ESR1 siRNA (MISSION® select predesigned siRNAs;
SASI_Hs01_00078594, Sigma-Aldrich Co.) and MIS-
SION® siRNA Universal Negative Control (Sigma-
Aldrich Co.) were transfected into established ERα (−)
and ERα (+) stable cells using Lipofectamine® RNAiMAX
Transfection Reagent (Invitrogen) according to the man-
ufacturer’s recommendations. For the dual-luciferase
reporter assay, 100 ng of each construct, the pNL1.1.TK
vector (0.25 ng) and ESR1 siRNA (50 nM) or siRNA
Universal Negative Control (50 nM) per well were
cotransfected in 96-well white-bottom plates using Lipo-
fectamine® 3000 Reagent (0.7 µl, Invitrogen) according to
the manufacturer’s recommendation.
Statistical analysis
Statistical analysis was conducted using SPSS (version
23.0.1; SPSS Inc., Chicago, IL, USA) or R software (version
3.4.0; Vienna, Austria).
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Results
ERα expression is associated with clinical and pathological
features of HCC
ERα expression was evaluated using immunohisto-
chemical staining of a TMA of samples from 339 HCC
patients. We observed that 9.4% (32/339) of the HCCs
expressed ERα (Fig. 1a). Clinicopathological features were
evaluated according to the expression of ERα, which
revealed that compared to ERα (−) HCCs, ERα (+) HCCs,
were significantly associated with older age (>60 years,
p < 0.05, Student’s T-test), lower serum AFP levels (3.6
IU/mL, p < 0.001, Student’s T-test), a lower incidence of
tumor microvascular invasion (38%, 12/32, p= 0.029,
Fisher’s exact test), and a higher incidence of fatty change
in the tumor (46.9%, 15/32, p= 0.017; Table 1).
Kaplan–Meier survival analysis revealed that the patients
with ERα (+) HCC had better prognostic outcomes of OS
(HR= 0.11, p= 0.009, Fisher’s exact test) and DFS (HR=
0.40, p= 0.013, Fig. 1b). Univariate and multivariate Cox
regression analyses also confirmed that ERα expression is
an independent predictor of the prognostic outcomes of
HCC patients (p < 0.05, one-way Chi-square test Table 2).
Identification of the molecular traits associated with ESR1
expression in HCC
To evaluate the molecular characteristics associated
with ERα expression, we analyzed the HCC transcriptome
data of the TCGA-LIHC dataset (n= 371)16. The HCC
patients were stratified according to the expression level
of ESR1 mRNA into the ESR1-high (ESR1-H, n= 185)
and ESR1-low (ESR1-L, n= 186) groups, with the median
value of the ESR1 level across the samples considered the
cutoff value. Unsupervised clustering analysis using vari-
ably expressed genes (median absolute deviation [MAD]
>0.5, n= 7094) revealed that the transcriptome of the
HCC patients was readily classifiable based on the ESR1
expression status. Specifically, 155 of 185 ESR1-H HCCs
(83.8%) and 148 of 186 ESR1-L HCCs (79.6%) were
clustered together (Supplementary Fig. S1), which may
indicate that the molecular traits of ERα expression are
well reflected in the HCC transcriptome. Next, we iden-
tified the differentially expressed genes (DEGs) between
the ESR1-H and ESR1-L HCC groups as the
ESR1 signatures “Sig ESR1-L” (n= 482) and “Sig ESR1-H”
(n= 785) (p < 10–6, permutation t-test with fold change
[FC] >0.5; Supplementary Table S4). Sig ESR1-H was
enriched with metabolism-related genes, including
CYP2A6 (FC= 3.83), CYP3A4 (FC= 3.78), CYP8B1 (FC=
3.38), and CYP1A2 (FC= 2.33) (Fig. 2a and Supplemen-
tary Fig. S2), whereas Sig ESR1-L exhibited enrichment
with stemness-related or tumor aggressiveness-related
genes, such as AFP (FC=−2.70), CD24 (FC=−2.27),
S100P (FC=−2.01), SPP1 (FC=−1.89), EPCAM (FC=
−1. 83), and KRT19 (FC=−1.01). Moreover, we found
that compared to the ESR1-H group, the -ESR1-L group
exhibited higher expression of HALLMARK oncogenic
features such as “MYC_TARGETS_V1” (n= 200),
“E2F_TARGET” (n= 200), “G2M_CHECKPOINT” (n=
200), “MYC_TARGETS_V2” (n= 58), and “UNFOL-
DED_PROTEIN_RESPONSE” (n= 113) (Supplementary
Fig. S3). In addition, we evaluated the expression of the
previously known prognostic classifiers of HCC (i.e.,
Fig. 1 ERα expression is associated with less aggressive clinical pathological features of HCC. a Histopathological images of ERα (−) and ERα
(+) HCC tissue. ERα is expressed in the nuclei of tumor cells. b Kaplan–Meier curves of overall survival and disease-free survival for patients with ERα
(+) (n= 32) and ERα (−) HCC (n= 307).
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TCGA subtype23, Hoshida’s classification18, Boyault’s
classification19, and liver cancer stem cell features17) in
the TCGA-LIHC dataset by applying the NTP algorithm
(for details, see Materials and Methods). The ESR1-L
group exhibited enrichment of the aggressive prognostic
classifiers such as iCluster1 in TCGA subtype, S1 and S2
in Hoshida’s classification, G1 and G3 in Boyault’s clas-
sification, and UP in liver cancer stem cell features (p <
0.001, chi-square test); in contrast, the ESR1-H group was
enriched in the less aggressive prognostic classifiers, such
as S3 in Hoshida’s classification, G5 and G6 in Boyault’s
classification, and DOWN in liver cancer stem cell fea-
tures (p < 0.001, chi-square test, Fig. 2b). When we cal-
culated the oncoactivity score for each sample based on
the differentially upregulated expression of the oncogenes
and counterbalanced suppression of the TSGs (i.e., ESon-
cogene− ESTSG) as described previously
24 (for details, see
Materials and Methods), we observed significantly higher
oncoactivity scores in ESR1-L patients than in ESR1-H
patients (p < 10−15, Fig. 2c). We also found that ESR1-L
patients expressed stemness- and tumor aggressiveness-
related genes (CD24, S100P, EPCAM, and KRT19), which
have been shown to play critical roles in the development
and progression of tumors25,26. This finding was validated by
immunohistochemical analysis of the 339 HCC specimens,
demonstrating the differential expression of EpCAM, K19,
CD133, CD24, and S100P between the ERα (+) and ERα (−)
HCCs (p < 0.05, Fisher’s exact test; Fig. 2d). Correspond-
ingly, Kaplan–Meier survival analysis revealed that the
ESR1-H patients exhibited better OS (HR= 0.53, p < 10−3)
and DFS (HR= 0.37, p < 10−3) than the ESR1-L patients
(Fig. 2e). ESR1-H status was also significantly associated with
older age (>62 years, p < 0.001) and a lower serum AFP level
(p < 0.001) (Supplementary Table S5). Univariate and mul-
tivariate analyses confirmed that ESR1 expression was an
independent prognostic predictor of the clinical outcomes of
patients in TCGA-LIHC (p < 0.05, Supplementary Table S6).
These results may strongly indicate that ERα (or ESR1)
expression is a good indicator of better prognostic outcomes
of HCC and is associated with alterations in the tran-
scriptomic traits of HCC.
Next, we further validated the class predictability of the
ESR1 signature by constructing a pooled dataset of HCC
transcriptomes (n= 447), including data from GSE87630
Table 1 Clinicopathological characteristics of patients with HCC according to the ERα protein expression level.
Clinicopathological feature ERα protein-positive HCCs ERα protein-negative HCCs p value
n= 32 (9.4%) n= 307 (90.6%)
Age (years; median, IQR) 60 (51–68) 55 (48–63) 0.015
Sex (male/female, %) 26 (81%)/6 (19%) 252 (83%)/53 (17%) 1
Etiology (HBV/HCV/Alcohol/Unknown, %) 25 (78%)/1 (3%)/1 (3%)/5 (16%) 252 (82%)/17 (6%)/14 (5%)/24 (8%) 0.462
Serum AST (IU/L; median, IQR) 28 (22–41) 30 (23–40) 0.934
Serum ALT (IU/L; median, IQR) 31 (20–49) 31 (22–45) 0.852
Serum albumin (g/dL; median, IQR) 4.3 (4.1–4.6) 4.4 (4.1–4.7) 0.61
Serum platelets (×1000/μL; median, IQR) 174 (119–201) 162 (133–210) 0.343
Serum alpha-fetoprotein (IU/mL; median, IQR)a 3.6 (2.5–27.1) 24.9 (4.6–279.5) <0.001
Serum PIVKA-II (AU/mL; median, IQR)b 58.0 (24.0–346.0) 81.0 (33.5–539.0) 0.189
TNM stage (stage I/II/III, %) 17 (53%)/14 (44%)/1 (3%) 105 (34%)/186 (61%)/16 (5%) 0.104
HCC pathology
Differentiation (Edmonson–Steiner Grade I/II/III, %) 5 (16%)/22 (69%)/5 (16%) 21 (7%)/224 (73%)/62 (20%) 0.193
Diameter of the largest tumor (cm; median, IQR) 2.7 (1.8–4.3) 3.2 (2.2–4.5) 0.782
Tumor multiplicity 3 (9%) 41 (13%) 0.075
Tumor capsule formation (absent/partial/complete, %) 5 (16%)/14 (44%)/13 (40%) 54 (18%)/168 (55%)/85 (28%) 0.302
Microvascular invasion (%) 12 (38%) 182 (59%) 0.029
Tumor fatty change (absent/present, %) 17 (53.1%)/15 (46.9%) 223 (73.1%)/82 (26.9%) 0.017
Nontumor liver pathology
Chronic hepatitis or cirrhosis (%) 30 (93.8%) 294 (95.8%) 0.642
IQR interquartile range, SD standard deviation.
aSerum alpha-fetoprotein was not available for one patient.
bSerum PIVKA-II was not available for 11 patients.
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Table 2 Univariate and multivariate Cox regression analysis of overall survival of HCC patients.
Variable Univariate analysis Multivariate analysis
No. of patients (n= 339) HR 95% C.I. p value HR 95% C.I. p value
Age (years) 1.3 0.78–2.1 0.33
≤60 224
>60 115
Sex 1.4 0.74–2.7 0.3
Male 277
Female 62
Serum ALT (IU/L) 1.2 0.65–2 0.62
≤50 274
>50 65
Serum AST (IU/L) 1.8 0.95–3.2 0.07
≤50 299
>50 40
Alpha-fetoprotein 1.6 0.85–2.9 0.15
≤1000 294
>1000 44
Albumin 0.9 0.5–1.6 0.32
≤4.5 219
>4.5 120
Cirrhosis 1.4 0.84–2.2 0.22
Absent 150
Present 189
Tumor size 1.6 0.98–2.5 0.62
<5 cm 264
≥5 cm 75
Tumor multiplicity 1.5 0.76–2.9 0.25
Absent 302
Present 37
Microvascular invasion 1.7 1–2.7 0.05 1.12 0.34–2.28 0.81
Absent 145
Present 194
Differentiation 1.9 1.1–3.2 0.027 1.76 0.64–4.79 0.27
I 122
II-III 217
ERα protein expression 0.24 0.07–0.8 0.031 0.25 0.08–0.83 0.038
Negative 307
Positive 32
HR hazard ratio, CI confidence interval.
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Fig. 2 Transcriptomic traits of HCC associated with the expression status of ESR1. a Heatmap showing the expression pattern of DEGs (Sig
ESR1-L, n= 482; Sig ESR1-H, n= 785). The top ten DEGs are indicated on the right side. b Boxplots showing the frequencies of the subtypes
predicted by the previous HCC classifiers (i.e., TCGA, Hoshida’s, Boyault’s, and liver cancer stem cell features). c Boxplot showing the oncoactivity
scores among the HCC subtypes. d Images of immunohistochemical staining for EpCAM, K19, CD133, CD24, and S100P in the HCC TMA. Bar charts
showing the differences in the expression of EpCAM, K19, CD133, CD24, and S100P between ERα (+) and ERα (−) HCCs. e Kaplan–Meier curves of OS
and DFS for patients in the ESR1-H (n= 185) and ESR1-L (n= 186) groups in TCGA-LIHC.
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(n= 64), GSE4024 (n= 139), and GSE14520 (n= 244). By
applying the NTP algorithm, we stratified the dataset into
three groups: ESR1-H (n= 201), ESR1-L (n= 177), and N.
D. (n= 69, not determined, FDR ≥.05; Fig. 3a). We
demonstrated the higher oncoactivity scores in the ESR1-
L group compared to the ESR1-L group in each of the
datasets (p < 0.001, Fig. 3b; for details, see Material and
Methods). In addition, we identified the DEGs between
the ESR1-H and ESR1-L groups (p < 0.01, permutation t-
test and FC >1.0), revealing that AFP expression had the
highest FC between the groups (FC= 3.34, p < 10−12). In
support of this finding, we observed that HCC samples
from patients with higher serum levels of AFP (>300 ng/
mL) were more frequently ERα (−) tumors than ERα (+)
tumors in our data and were more frequently ESR1-L
tumors than ESR1-H tumors in TCGA-LIHC data (p <
0.001, chi-square test; Fig. 3c). Kaplan–Meier survival
analysis also successfully demonstrated the prognostic
significance of ESR1 expression in the pooled dataset (n=
378, HR= 0.46, p < 10−5; Fig. 3d). Considering these
results collectively, we suggest that ESR1 expression plays
a pivotal role in transcriptomic alterations in association
with the heterogeneous progression of HCC.
ERα expression inhibits HCC progression by inactivating
the YAP pathway
We next sought to identify the underlying key down-
stream molecules that potentially drive the aggressive
phenotype of ESR1-L. We constructed a genetic network
of Sig ESR1-L by using the KEGG and REAC databases
(for details, see Materials and Methods) and found that
the gene set of cell cycle-related genes (9.95%, 42/482)
was the most significantly enriched (Fig. 4a and Supple-
mentary Fig. S2). We found that among the cell cycle-
related genes, YAP-related target genes (i.e., MYBL2,
CDC20, BIRC5, AURKB, TOP2A, and CENPF) and G2/M-
related genes were more highly differentially expressed in
ESR1-L than in ESR1-H (Fig. 4b). Gene set enrichment
analysis also revealed enriched expression of
“YAP1_UP”27 and “YAP_CONSERVED_SIG”28 genes in
ESR1-L (p < 0.05, Fig. 4c). Indeed, YAP binding to B-MYB
(encoded by the MYBL2 gene) is known to induce the
expression of G2/M genes29. Moreover, we found that the
promoter regions of the Sig ESR1-L genes frequently
contained the predicted transcription factor (TF) binding
sites for TEA domain family members (TEADs) (Fig. 4d),
which are known to be activated by YAP12. Thus, it is
Fig. 3 Validation of the functional and clinical significance of ESR1 expression in a pooled HCC dataset. a Heatmap showing the shared
differentially upregulated (ESR1-L; n= 63) and downregulated (ESR1-H; n= 199) genes in a pooled dataset including GSE87630, GSE4024, and
GSE14520. The DEGs in the pooled dataset were defined as genes with a fold change >1 and were assessed using Student’s t-test (p < 0.01) in the
comparison of ESR1-H with ESR1-L. b Boxplots showing the oncoactivity score (the enrichment score for the transition from an oncogene to a TSG
signature) of each group. c Plots showing the serum levels of AFP in the Yonsei cohort and TCGA-LIHC. d Kaplan–Meier OS curve for patients with
ESR1-H and ESR1-L HCCs.
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plausible that ESR1 expression may inactivate the YAP
pathway, resulting in suppression of cell cycle-related
genes and tumor progression.
To verify whether ESR1 expression can affect the YAP
pathway, we established an ERα overexpression system in
liver cancer cell lines (HepG2 and Hep3B) that have lower
expression levels of ESR1 (Supplementary Fig. S4a). We
demonstrated the tumor-suppressive effect of ERα (+)
cells compared to ERα (−) cells (p < 0.001, Supplementary
Fig. S4b). In addition, we evaluated whether ERα expres-
sion can regulate YAP activity by examining the cytosolic
and nuclear levels of YAP using Western blot and
immunofluorescence analyses. We demonstrated that
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suppressed the nuclear translocation of YAP (Fig. 4e, f).
Furthermore, by performing YAP/TAZ reporter assays,
we demonstrated that compared to ERα (−) cells, ERα (+)
cells markedly suppressed YAP transactivation (all p <
0.001, Fig. 4g). Additionally, we observed that the
expression of TEAD target genes (i.e., MYBL2, CDC20,
and TOP2A) was suppressed in ERα (+) cells compared
with ERα (−) cells (Fig. 4h). These results suggest that
ERα expression leads to inactivation of YAP and sup-
pression of its downstream target genes.
ERα-induced YAP inactivation may be mediated by Hippo
activation
Next, to identify the mechanisms underlying YAP
inactivation by ERα, we examined the YAP phosphoryla-
tion status. Compared to ERα (−) cells, ERα (+) cells
exhibited enhanced phosphorylation of YAP at Ser109
and Ser127 (Fig. 5a). As these sites were previously found
to be phosphorylated by LATS1 and MAST1/2, core
regulatory kinase proteins in the Hippo pathway30,31, we
further evaluated whether Hippo signaling is also involved
in ERα-mediated YAP inactivation. We demonstrated that
Hippo pathway genes (Reactome_signaling_by_hippo,
n= 20) were prominently expressed in the ESR1-H group
compared to the ESR1-L group in the TCGA-LIHC
dataset (p= 0.048, NES= 1.14, Fig. 5b). In support of this
finding, phosphorylation of the upstream Hippo signaling
molecules LATS1 and MST1/2 was increased in ERα (+)
cells compared with ERα (−) cells (Fig. 5c)12,32. These
results suggest that ERα-induced YAP inactivation is
mediated at least in part through activation of Hippo
signaling.
To further verify the effect of ERα on YAP, we per-
formed small interfering RNA (siRNA)-mediated ESR1
knockdown experiments. Transfection of siRNAs target-
ing ESR1 suppressed ERα-induced phosphorylation of
YAP and MST1/2 (Fig. 5d). In addition, we evaluated
YAP/TAZ promoter activities by cotransfecting the YAP/
TAZ reporter construct with ESR1 siRNA, and the results
revealed that ESR1 knockdown enhanced the suppressive
effect of ERα on YAP/TAZ promoter activity (Fig. 5e).
Furthermore, we validated our findings by immunohis-
tochemical staining analysis of YAP in HCC tissues. ERα
(−) HCC specimens showed increased nuclear expression
of YAP (34.9%, p= 0.01) compared with that in ERα (+)
HCC specimens (12.5%), although the cytoplasmic
expression levels of YAP were not different between the
groups (Fig. 5f). Considering these results collectively, we
suggest that ERα enhances the phosphorylation of Hippo/
YAP signaling molecules and attenuates downstream
signaling in this pathway, which in turn results in sup-
pression of HCC growth.
Discussion
In this study, we demonstrated that ERα expression is
an independent predictor of better prognostic outcomes
of HCC patients. In addition, by performing tran-
scriptome data analyses, immunohistochemistry, and cell
culture experiments, we demonstrated that the YAP
pathway is involved in ERα-mediated suppression of HCC
growth.
Previously, numerous studies have shown that YAP/TAZ
function as oncogenes in many cancers33. Activated YAP
can sustain positive feedback for the expression of cell
cycle-related genes to promote tumorigenesis34,35. More-
over, YAP has been shown to induce the expression of
stemness-related genes, promoting an aggressive tumor
phenotype33. Indeed, YAP can reprogram nonstem tumor
cells into cells with cancer stem cell attributes36. Corre-
spondingly, the association of YAP with less favorable
prognostic outcomes has been reported in HCC37,38.
However, contradictory evidence for the tumor-suppressive
functions of YAP/TAZ has also been reported39. A recent
study showed that YAP/TAZ exert a tumor-promoting
(see figure on previous page)
Fig. 4 YAP may mediate the aggressive phenotype of ESR1-L HCC. a A genetic network of Sig ESR1-L genes was constructed showing physical
interactions (pink), genetic interactions (green), and pathways (blue) by using GeneMANIA software in Cytoscape (version 3.4.1). Cell cycle-related
genes and YAP target genes in Sig ESR1-L are indicated. b Plot showing the gradually increase in ESR1 expression (top). Heatmap showing the
expression of YAP target genes and cell cycle-related genes in Sig ESR1-L (bottom). Cell cycle groups, such as G0/early G1-, G1/S-, G2/M-, and mitosis-
related groups, are indicated. c GSEA results showing the enrichment of YAP activation-related signatures (e.g., YAP1_UP and YAP_CONSERVED_SIG).
d Bar plots showing the frequency of transcription factors binding to the promoters of the top-ranked genes in Sig ESR1-L (n= 50). This database was
investigated using GeneHancer (https://www.genecards.org/). e The amount of YAP protein that translocated from the cytosol into the nucleus was
assessed by Western blotting after nucleocytoplasmic fractionation. GAPDH and histone H3 were used as nuclear and cytoplasmic control markers,
respectively (left). The amount of YAP protein that was translocated from the cytosol into the nucleus was assessed by Western blotting after
nucleocytoplasmic fractionation using ImageJ (1.8.0_172) (right). f Confocal immunofluorescence of YAP and 4′,6-diamidino-2-phenylindole (DAPI).
DAPI (blue) and YAP (green) were detected by confocal microscopy as described in the Materials and Methods. g Dual-luciferase assays showed that
the enhanced normalized relative luminescence unit (RLU) value of the 8xGTIIC construct was decreased in ERα-expressing HCC cell lines. The
pGL3.0-basic vector was used as a control (Ctrl). Statistical significance is indicated (Ctrl vs. ERα; *p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t-test).
h Bar plots showing the expression of YAP target genes (e.g., MYBL2, CDC20, and TOP2A) in ERα (+) and ERα (−) liver cancer cell lines (HepG2
and Hep3B). The expression levels of each gene were normalized to the expression level of ACTB. The data were presented as the mean ± SD values
(***p < 0.001, Student’s t-test).
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function but that activation of YAP/TAZ in peritumoral
hepatocytes can suppress primary liver tumor progres-
sion40. This pattern may indicate that YAP/TAZ exhibit
both tumor-suppressive and tumor-promoting activity
depending on their expression in tissues.
We demonstrated that ERα inactivates YAP signaling,
resulting in suppression of HCC growth. A recent study
demonstrated that the YAP1 and TEAD4 proteins act as
coregulators of ERα on enhancers41. Binding of YAP1/
TEAD4 to ERα-bound enhancers is required for the
Fig. 5 ERα expression attenuates the translocation of YAP via phosphorylation of MST1/2. a Expression of YAP and phosphorylation of YAP at
Ser109 and Ser127 were shown by Western blot analysis. b GSEA results showing the enriched expression of Hippo pathway-related genes. NES
normalized enrichment score. c Levels of phospho-MST1/2 (T183/180), MST1, phospho-LATS1 (S1079), and LATS1 were shown by Western blot
analysis. d ESR1 siRNA (50 nM) was used to treat ERα (+) HCC cell lines, and the phosphorylation of YAP (Ser127 and S109) and MST1/2 (T183/180)
was shown by Western blot analysis. e Bar plots showing the normalized RLU values of the 8xGTIIC construct in the absence of ERα resulting from
transfection of ESR1 siRNA (50 nM) in HepG2 (left) and Hep3B (right) liver cancer cells. The pGL3.0-basic vector (Ctrl) and NC (nontarget control) siRNA
were used as controls. Statistical significance is indicated (*p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t-test). f Immunohistochemical analysis of
YAP showing its nuclear and cytoplasmic expression in ERα (−) and ERα (+) HCCs (left). Boxplots showing significant differences in nuclear and
cytoplasmic expression of the YAP protein between ERα (−) and ERα (+) HCCs (p < 0.05, Fisher’s exact test; right).
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induction of ERα target genes and tumor growth. How-
ever, the effect of ERα on the YAP pathway has not been
clearly shown. We demonstrated that the expression of
ERα triggers the phosphorylation of Hippo kinases
(LATS1 and MST1) and YAP, which attenuates the
nuclear translocation of YAP.
It should be noted that we did not evaluate how ERα
phosphorylates Hippo/YAP proteins, requiring further
extended studies in the near future. In addition, many of
the multifaceted interactions of the Hippo/YAP pathways
have been shown previously, including those that induce
changes in mechanotransduction, inflammation, and
oncogenic signaling33, which should be evaluated to
understand more relevant mechanisms of ERα expression
in HCC progression.
In conclusion, we suggest that the expression of ERα is
an independent predictor of more favorable prognostic
outcomes in HCC patients. Inactivation of YAP by ERα
may contribute to the acquisition of a less aggressive
phenotype by HCC tumors. Thus, targeting YAP could be
a promising therapeutic strategy, especially for patients
with ERα (−) HCC.
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